Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Pembrolizumab Plus Vorinostat for Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma

NCT03150329 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT03150329
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03150329 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Pembrolizumab Plus Vorinostat for Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 18, 2017
Completion date
June 2, 2027
Enrollment
52 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

grade 3b follicular lymphoma, recurrent b-cell lymphoma, unclassifiable, with features intermediate between dlbcl and classic hl, recurrent classic hodgkin lymphoma, recurrent diffuse large b-cell lymphoma, recurrent follicular lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3a follicular lymphoma, recurrent primary mediastinal (thymic) large b-cell cell lymphoma, recurrent transformed non-hodgkin lymphoma, refractory b-cell lymphoma, unclassifiable, with features intermediate between dlbcl and classic hl, refractory classic hodgkin lymphoma, refractory diffuse large b-cell lymphoma, refractory follicular lymphoma, refractory primary mediastinal (thymic) large b-cell cell lymphoma, refractory transformed non-hodgkin lymphoma